

US Family Health Plan Prior Authorization Request Form for Secukinumab (Cosentyx)

To be completed and signed by the prescriber. To be used only for prescriptions which are to be filled through the Department of Defense (DoD) US Family Health Plan Pharmacy Program. US Family Health Plan is a TRICARE contractor for DoD.

The completed form may be faxed to 855-273-5735

OR

The patient may attach the completed form to the prescription and **mail** it to:
Attn: Pharmacy, 77 Warren St, Brighton, MA 02135

QUESTIONS? **Call 1-877-880-7007**

Clinical documentation may be required for approval.

Step 1 Please complete patient and physician information (please print):

Patient Name: _____	Physician Name: _____
Address: _____	Address: _____
Sponsor ID # _____	Phone #: _____
Date of Birth: _____	Secure Fax #: _____

Step 2 Please complete clinical assessment:

1. Humira is the Department of Defense's preferred targeted biologic agent. Has the patient tried Humira?	<input type="checkbox"/> Yes Proceed to question 2	<input type="checkbox"/> No Proceed to question 4
2. Has the patient had an inadequate response to Humira?	<input type="checkbox"/> Yes Proceed to question 5	<input type="checkbox"/> No Proceed to question 3
3. Has the patient experienced an adverse reaction to Humira that is not expected to occur with the requested agent?	<input type="checkbox"/> Yes Proceed to question 5	<input type="checkbox"/> No STOP Coverage not approved
4. Does the patient have a contraindication to Humira (adalimumab)?	<input type="checkbox"/> Yes Proceed to question 5	<input type="checkbox"/> No STOP Coverage not approved
5. Is the patient 18 years of age or older?	<input type="checkbox"/> Yes Proceed to question 6	<input type="checkbox"/> No Proceed to question 7
6. What is the indication or diagnosis for this adult patient?	<input type="checkbox"/> Active psoriatic arthritis (PsA) – Proceed to question 11 <input type="checkbox"/> Moderate to severe plaque psoriasis in a patient who is a candidate for systemic therapy or phototherapy – Proceed to question 11 <input type="checkbox"/> Active ankylosing spondylitis (AS) – Proceed to question 12 <input type="checkbox"/> Active non-radiographic axial spondyloarthritis (nr-axSpA) with objective signs of inflammation – Proceed to question 12 <input type="checkbox"/> Moderate to severe hidradenitis suppurativa (HS) – Proceed to question 11 <input type="checkbox"/> Other indication or diagnosis – STOP: coverage not approved.	

US Family Health Plan Prior Authorization Request Form for
secukinumab (Cosentyx)

<p>7. What is the indication or diagnosis for this pediatric patient?</p>	<p><input type="checkbox"/> Moderate to severe plaque psoriasis in a patient who is a candidate for systemic therapy or phototherapy – Proceed to question 8</p> <p><input type="checkbox"/> Active enthesitis-related arthritis (ERA) – Proceed to question 9</p> <p><input type="checkbox"/> Active psoriatic arthritis (PsA) – Proceed to question 10</p> <p><input type="checkbox"/> Other indication or diagnosis – STOP: coverage not approved</p>	
<p>8. How old is the patient?</p>	<p><input type="checkbox"/> Greater than or equal to 6 years of age and Less than or equal to 17 years of age - Proceed to question 11</p> <p><input type="checkbox"/> Other – STOP Coverage not approved</p>	
<p>9. How old is the patient?</p>	<p><input type="checkbox"/> Greater than or equal to 4 years of age and Less than or equal to 17 years of age - Proceed to question 13</p> <p><input type="checkbox"/> Other – STOP Coverage not approved</p>	
<p>10. How old is the patient?</p>	<p><input type="checkbox"/> Greater than or equal to 2 years of age and Less than or equal to 17 years of age -Proceed to question 11</p> <p><input type="checkbox"/> Other – STOP Coverage not approved</p>	
<p>11. Has the patient had an inadequate response to non-biologic systemic therapy? For example: methotrexate, aminosalicylates [for example, sulfasalazine, mesalamine], corticosteroids, immunosuppressants [for example, azathioprine], antibiotics, anti-androgens, etc.</p>	<p><input type="checkbox"/> Yes Proceed to question 13</p>	<p><input type="checkbox"/> No STOP Coverage not approved</p>
<p>12. Has the patient had an inadequate response to at least two NSAIDS over a period of at least two months?</p>	<p><input type="checkbox"/> Yes Proceed to question 13</p>	<p><input type="checkbox"/> No STOP Coverage not approved</p>
<p>13. Does the patient have evidence of a negative TB test result in the past 12 months (or TB is adequately managed)?</p>	<p><input type="checkbox"/> Yes Proceed to question 14</p>	<p><input type="checkbox"/> No STOP Coverage not approved</p>
<p>14. Will the patient be receiving other targeted immunomodulatory biologics with Cosentyx, including but not limited to the following: Actemra, Cimzia, Enbrel, Humira, Ilumya, Kevzara, Kineret, Olumiant, Orenzia, Otezla, Remicade, Rinvoq ER, Rituxan, Siliq, Simponi, Skyrizi, Stelara, Taltz, Tremfya or Xeljanz/Xeljanz XR?</p>	<p><input type="checkbox"/> Yes STOP Coverage not approved</p>	<p><input type="checkbox"/> No Sign and date below.</p>

**Step
3**

I certify the above is true to the best of my knowledge. Please sign and date:

_____ Prescriber Signature

_____ Date